Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs

AIDS

Volumn 15, Issue 5, 2001, Pages 617-620

  Moore, Richard D ^a   Keruly, Jeanne C ^a   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Didanosine; Hydroxyurea; Nucleosides; Pancreatitis; Toxicity

Indexed keywords

DIDANOSINE; HYDROXYUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

ADULT; AMYLASES; ANTI-HIV AGENTS; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; INCIDENCE; LIPASE; LONGITUDINAL STUDIES; MALE; PANCREATITIS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; UNITED STATES; ZIDOVUDINE;

EID: 0035970704     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103300-00011     Document Type: Article

References (11)

1. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection
2. The didanosine expanded access program: Safety analysis
3. Hepatomegaly with severe steatosis in HIV-seropositive patients
4. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
5. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
6. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
7. Randomized trial of continued indinavir (IDV)/ZDV/3TC vs. switch to IDS/ddl/d4T or IDV/ddl/d4T +hydroxyurea in patients with viral suppression
8. Incidence of neuropathy in HIV-infected patients taking monotherapy vs. combination therapy with didanosine, stavudine, and hydroxyurea
9. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort
10. Pancreatitis incidence rates of patients treated in 20 adult antiretroviral treatment trials
11. Rates and risk factors for adverse events associated with didanosine in the expanded access program